These results provide a better understanding regarding the importance of genetic events, and the study emphasizes a need to pay attention to the Ph-positive B-ALL patients with CDKN2 deletion who could potentially benefit from anti-CD20-directed immunotherapy. This evidence concerns the gene CDKN2A and acute lymphoblastic leukemia.